Erlotinib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Trial Timeline
Mar 31, 2011 → Sep 29, 2017
NCT ID
NCT01260181About Erlotinib
Erlotinib is a phase 2 stage product being developed by Roche for Non-Squamous Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01260181. Target conditions include Non-Squamous Non-Small Cell Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Non-Squamous Non-Small Cell Lung Cancer were approved
Approved (3) Terminated (1) Active (16)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01990261 | Pre-clinical | Terminated |
| NCT01667562 | Phase 3 | Completed |
| NCT01470716 | Phase 2 | UNKNOWN |
| NCT01664533 | Pre-clinical | Completed |
| NCT01153984 | Phase 2 | Completed |
| NCT01310036 | Phase 2 | Completed |
| NCT01378962 | Phase 2 | Completed |
| NCT01260181 | Phase 2 | Completed |
| NCT01230710 | Approved | Completed |
| NCT01085838 | Phase 1/2 | Completed |
| NCT02595450 | Pre-clinical | Completed |
| NCT01161173 | Pre-clinical | Completed |
| NCT00452075 | Phase 2 | Terminated |
| NCT00391248 | Phase 2 | Completed |
| NCT00339586 | Phase 2 | UNKNOWN |
| NCT02774278 | Phase 2 | Completed |
| NCT00949910 | Approved | Completed |
Competing Products
20 competing products in Non-Squamous Non-Small Cell Lung Cancer